GRACE is excited to bring to our Spanish speaking community a new series on Cancer Myths Our friend and partner, Narjust (N.J.) Duma, MD is a Chief...
GRACE is excited to bring to our Spanish speaking community a new series on Cancer Myths Our friend and partner, Narjust (N.J.) Duma, MD is a Chief...
GRACE is excited to bring to our Spanish speaking community a new series on Cancer Myths Our friend and partner, Narjust (N.J.) Duma, MD is a Chief...
GRACE is excited to bring to our Spanish speaking community a new series on Cancer Myths Our friend and partner, Narjust (N.J.) Duma, MD is a Chief...
GRACE is excited to bring to you more in our new series on surviving with cancer GRACE is excited to bring to you more in our series on surviving with...
Drs. Ben Solomon, Leora Horn, & Jack West discuss highlights of a French randomized trial that demonstrated a significant survival benefit from addition of Avastin (bevacizumab) to cisplatin/Alimta in patients with malignant pleural mesothelioma.
Drs. Ben Solomon, Leora Horn, & Jack West review trial result and implications of ECOG 1505 trial that showed no benefit to addition of Avastin (bevacizumab) to adjuvant chemotherapy for early stage NSCLC.
Dr. Eddie Garon from UCLA Medical Center reviews the general mechanism of action of immune checkpoint inhibitors and how they can be an effective therapy in lung cancer.
Dr. Greg Riely, medical oncologist from MSKCC, discusses the controversial question of whether patients should continue on an oral EGFR tyrosine kinase inhibitor after progression.
MSKCC medical oncologist Dr. Greg Riely explains the growing value of a repeat biopsy after the development of acquired resistance in patients with an EGFR mutation.
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.